Immunology and Biotherapies
38.0K views | +0 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

New Cell Sources for T Cell Engineering and Adoptive Immunotherapy

New Cell Sources for T Cell Engineering and Adoptive Immunotherapy | Immunology and Biotherapies | Scoop.it
From www.sciencedirect.com - April 13, 2015 7:04 AM

The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 13, 2015 5:49 AM

Volume 16, Issue 4, 2 April 2015, Pages 357–366

3601||

Perspective New Cell Sources for T Cell Engineering and Adoptive ImmunotherapyMaria Themeli1, Isabelle Rivière1, Michel Sadelain1, ,   doi:10.1016/j.stem.2015.03.011
Sign up to comment
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

Cancer Gene Therapy - Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

Cancer Gene Therapy - Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies | Immunology and Biotherapies | Scoop.it
From news.google.com - April 3, 2015 3:21 PM
Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, February 28, 2015 11:34 AM

Review

Cancer Gene Therapy advance online publication 27 February 2015; doi: 10.1038/cgt.2014.81

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

X Wang1,2 and I Rivière1,2,3

1Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA2Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA3Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Correspondence: Dr I Rivière, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 182, New York, NY 10065, USA. E-mail: rivierei@mskcc.org

Received 21 October 2014; Accepted 10 December 2014
Advance online publication 27 February 2015
Sign up to comment
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

Cancer Gene Therapy - Towards a commercial process for the manufacture of genetically modified T cells for therapy

Cancer Gene Therapy - Towards a commercial process for the manufacture of genetically modified T cells for therapy | Immunology and Biotherapies | Scoop.it
From www.nature.com - March 14, 2015 2:30 PM

Abstract

The recent successes of adoptive T-cell immunotherapy for the treatment of hematologic malignancies have highlighted the need for manufacturing processes that are robust and scalable for product commercialization. Here we review some of the more outstanding issues surrounding commercial scale manufacturing of personalized-adoptive T-cell medicinal products. These include closed system operations, improving process robustness and simplifying work flows, reducing labor intensity by implementing process automation, scalability and cost, as well as appropriate testing and tracking of products, all while maintaining strict adherence to Current Good Manufacturing Practices and regulatory guidelines. A decentralized manufacturing model is proposed, where in the future patients’ cells could be processed at the point-of-care in the hospital.


Via Krishan Maggon
Gilbert C FAURE's insight:

OPEN

more...
Krishan Maggon 's curator insight, March 14, 2015 1:39 PM

Cancer Gene Therapy (2015) 22, 72–78; doi:10.1038/cgt.2014.78; published online 23 January 2015

Towards a commercial process for the manufacture of genetically modified T cells for therapy
OPEN

A D Kaiser1, M Assenmacher1, B Schröder1, M Meyer1, R Orentas2, U Bethke1and B Dropulic2

1Miltenyi Biotec GmbH, Bergisch Gladbach, Germany2Lentigen Technology Inc., Gaithersburg, MD, USA

Correspondence: Dr A Kaiser, Miltenyi Biotec GmbH, Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany. E-mail: andrewk@miltenyibiotec.de; B Dropulic, Lentigen Technology Inc., 910 Clopper Road, Gaithersburg, MD, USA. E-mail: boro.dropulic@lentigen.com

Received 22 October 2014; Accepted 5 November 2014
Advance online publication 23 January 2015
Sign up to comment
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic

From www.sciencedirect.com - February 4, 2015 2:02 PM
Highlights

 

•

The presence of immune infiltrate in tumors has been correlated with a good prognosis following treatment.

•

Tumor-infiltrating lymphocytes have been utilized for the treatment of melanoma.

•

To broaden this therapy for other cancers, T cells have been genetically modified with either a T cell receptor or a chimeric antigen receptor.

•

Potential hurdles and novel strategies will be discussed for realizing the full potential of adoptive immunotherapy becoming a standard of care treatment for cancer.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, January 30, 2015 8:49 AM
Molecular Immunology

Available online 13 January 2015

In Press, Corrected Proof — Note to users

Review Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic ☆Connie P.M. Duonga, b, c, Carmen S.M. Yonga, b, Michael H. Kershawa, b, c, d, Clare Y. Slaneya, b, 1, , ,Phillip K. Darcya, b, c, d, 1, ,  doi:10.1016/j.molimm.2014.12.009
Sign up to comment
About Follow us Resources Terms Mobile Features
Facebook
X
LinkedIn